North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-01-05 Ipilimumab

Ipilimumab Yervoy®
Formulary
  • Approved for previously treated advanced melanoma in line with NICE.
  • Approved for previously untreated advanced melanoma in line with NICE.
  • Approved in combination with nivolumab for untreated renal cell carcinoma in line with NICE.
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Link  MHRA Drug Safety Update (Jan 2019): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation

Cytotoxic Drug  Red View adult BNF  View SPC online  View childrens BNF  HCD